Emily L. Heil
-
- Antibiotic Use and Resistance 42
- Molecular Medicine top 0.5%
- Antibiotic Resistance in Bacteria 30
- Clinical Biochemistry top 0.5%
- Bacterial Identification and Susceptibility Testing 38
- Pharmacology top 1%
- Antibiotics Pharmacokinetics and Efficacy 46
- Infectious Diseases top 2%
- Antimicrobial Resistance in Staphylococcus 34
- Clostridium difficile and Clostridium perfringens research 14
-
- Pneumonia and Respiratory Infections 16
- Urinary Tract Infections Management 10
Emily L. Heil
129 papers receiving 2.5k citations
Hit Papers
Peers
Comparison fields: 5 of 119
- Applied Microbiology and Biotechnology 744
- Molecular Medicine 748
- Clinical Biochemistry 608
- Pharmacology 905
- Infectious Diseases 646
Countries citing papers authored by Emily L. Heil
This map shows the geographic impact of Emily L. Heil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily L. Heil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily L. Heil more than expected).
Fields of papers citing papers by Emily L. Heil
This network shows the impact of papers produced by Emily L. Heil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily L. Heil. The network helps show where Emily L. Heil may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Emily L. Heil, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infectionsbreakdown → | 2024 | 328 |
| 4 | 2023 | 16 | |
| 5 | 2023 | 20 | |
| 6 | 2023 | 2 | |
| 7 | 2023 | 1 | |
| 8 | 2022 | 16 | |
| 9 | 2022 | 3 | |
| 10 | 2022 | 17 | |
| 11 | 2021 | 6 | |
| 12 | 2021 | 8 | |
| 13 | 2021 | 2 | |
| 14 | 2020 | 16 | |
| 15 | 2020 | 7 | |
| 16 | 2020 | 25 | |
| 17 | 2020 | 24 | |
| 18 | 2019 | 4 | |
| 19 | 2018 | 16 | |
| 20 | 2016 | 30 |
About Emily L. Heil
Emily L. Heil is a scholar working on Applied Microbiology and Biotechnology, Molecular Medicine and Clinical Biochemistry, having authored 139 papers that have together received 2.6k indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (46 papers), Antibiotic Use and Resistance (42 papers), Bacterial Identification and Susceptibility Testing (38 papers), Antimicrobial Resistance in Staphylococcus (34 papers), Antibiotic Resistance in Bacteria (30 papers), Pneumonia and Respiratory Infections (16 papers), Clostridium difficile and Clostridium perfringens research (14 papers) and Urinary Tract Infections Management (10 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (744 citations), Molecular Medicine (748 citations) and Clinical Biochemistry (608 citations). Emily L. Heil has collaborated with scholars based in United States, Zambia and Canada. Frequent co-authors include J. Kristie Johnson, Pranita D. Tamma, Kimberly C. Claeys, Julie Ann Justo, Amy J. Mathers, Robert A Bonomo, Michael J. Satlin, Jacqueline Bork, Jeffrey R. Strich and Henry Masur.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.